GTEx Ovary 20-29 vs 40-49 Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx Ovary 20-29 vs 40-49 Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx Ovary 20-29 vs 40-49 Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx Ovary 20-29 vs 40-49 Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx Ovary 20-29 vs 40-49 Down.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 707

Gene

long intergenic non-protein coding RNA 1224

Gene

MIR124-1 host gene

Gene

sialic acid binding Ig like lectin 17, pseudogene

Gene

long intergenic non-protein coding RNA 923

Gene

SSTR5 antisense RNA 1

Gene

long intergenic non-protein coding RNA 968

Gene

uncharacterized LOC93429

Gene

endothelin converting enzyme like 1 pseudogene 2

Gene

transmembrane protein 238 like

  • Gene

    long intergenic non-protein coding RNA 707


  • Gene

    long intergenic non-protein coding RNA 1224



  • Gene

    sialic acid binding Ig like lectin 17, pseudogene


  • Gene

    long intergenic non-protein coding RNA 923


  • Gene

    SSTR5 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 968


  • Gene

    uncharacterized LOC93429


  • Gene

    endothelin converting enzyme like 1 pseudogene 2


  • Gene

    transmembrane protein 238 like

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.